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systemic levels of interleukin-6 in mice. 
It has also been shown that treatment of 
diabetes with thiazolidinediones selec-
tively increases fat partitioning to the 
subcutaneous adipose depot but does 
not change visceral fat accumulation.6 It 
is possible that thiazolidinediones could 
prevent all three types of fat redistribu-
tion discussed in this Commentary.
In summary, tissue lipid redistribution 
and accumulation in response to 
inflammation may occur at several lev-
els and sites: from circulation to tissue, 
tissue to tissue, and organelle to organelle 
(Figure 1). Human adipose tissue does 
not exist in isolation in different anatomic 
locations, and a best-fit relationship in 
terms of volume and function among 
different fat depots needs to be met to 
maintain energy homeostasis and prevent 
obesity-related complications. Therefore, 
the topography of adipose tissue is an 
important and timely addition to con-
ventional measurements of plasma lipid 
concentration and increases understand-
ing of the pathogenesis of lipid-mediated 
renal and vascular injury while providing 
new targets for therapeutic intervention.
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Does an apple a day put 
hypertension in play?
Joachim Jankowski1 and Thomas Günthner1
Singh et al. offer exciting data in their new report about fructose-induced 
hypertension. Fructose induced an increase in serum uric acid after 8–10 
weeks of increased fructose exposure, but no correlation was found 
between hyperuricemia and hypertension.
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Research on the role of fructose has 
increased but has demonstrated ambigu-
ous outcomes. Although some showed 
that fructose markedly lowers postpran-
dial hyperglycemia and hyperinsulinemia1 
and improves glucose tolerance in type 2 
diabetes patients,2 the majority of publica-
tions found no benefits. Fructose has been 
described as an elicitor of insulin resistance, 
dyslipidemia, disordered carbohydrate 
metabolism, hypertension, and obesity.3,4 
Singh et al.5 (this issue) now describe a 
fructose-induced increase in serum uric 
acid after 8–10 weeks of increased fruc-
tose exposure, which was also found by 
Nakagawa et al.6 However, unlike those 
authors, Singh et al.5 found no correlation 
between hyperuricemia and hypertension. 
This association needs to be taken into con-
sideration by Singh et al., who consider it 
a consequence of salt overload and hyper-
volemia. A recently published study reveals 
that the fructose transporter SLC2A9 also 
transports uric acid and hence may provide 
the explanation for hyperuricemia.7
Singh et al.5 impressively demonstrate 
an increased expression of the apical 
chloride-absorbing transporter (PAT1/
Slc26a6) and the fructose-absorbing 
transporter (Glut5/Slc2a5) in the small 
intestine in mice, stimulated by increased 
dietary fructose intake. The outstanding 
findings of their paper clarify the mecha-
nism of fructose-induced hypertension. 
The study is well designed, and the data 
presented are valid. However, the number 
of animals used in the experiments is very 
limited: three, four, and five. A uniform 
number of animals would be desirable. 
Another weakness of the study is the sole 
use of a 40 mM concentration of fruc-
tose solution, which is rather high. An 
analysis and comparison of the observed 
effects using additional lower concentra-
tions would probably deliver information 
regarding a dose–response relationship.
The authors proved an interaction 
between the two above-mentioned trans-
porters.5 The fructose-induced increase 
in intestinal chloride absorption and a 
simultaneous decrease in renal chloride 
excretion led to salt overload and eventu-
ally generated hypertension in Slc26a6+/+ 
mice. Fructose-induced blood pressure 
elevation was 9 ± 1.3 mm Hg in Slc26a6+/+ 
and 3 ± 0.3 mm Hg in Slc26a6–/– mice. 
On the other hand, the plasma fructose 
increase was comparable in Slc26a6+/+ and 
Slc26a6–/– mice, which indicates that dele-
tion of Slc26a6 did not affect the absorption 
of fructose in the intestine. These effects 
were confirmed in experiments in Sprague-
Dawley rats. Increased dietary fructose 
significantly elevated systolic blood pres-
sure as compared with a control diet. The 
removal of chloride from the high-fructose 
diet blocked fructose-induced hyperten-
sion by 70% when compared with the 
chloride-free diet alone and by 100% when 
compared with the control diet.
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Intestinal fluid absorption dependent on 
fructose stimulation was also examined in 
mice. Proximal jejunum was perfused in 
vivo with isotonic perfusate, and net fluid 
absorption was examined before and 
after the addition of fructose. The basal 
fluid absorption was reduced by 25% in 
Slc26a6–/– mice compared with Slc26a6+/+ 
mice. Fructose increased fluid absorption 
significantly in Slc26a6+/+ mice, a response 
that was blunted in Slc26a6–/– mice. The 
claim that the magnitude of fructose- 
stimulated fluid absorption would be 110% 
higher in Slc26a6+/+ mice compared with 
Slc26a6–/– mice is questionable, as there is 
a dependence on the original absorption 
volume of the fructose-free salt solution, 
which is clearly lower in Slc26a6–/– mice 
than in Slc26a6+/+ mice. In addition to 
comparison of the increased absorption 
as an absolute volume (per centimeter, per 
hour), the percentage increase of absorp-
tion should be compared, which would 
result in a lower magnitude.
Importantly, the authors found a 45% 
decrease in renin expression in the kid-
neys of animals on increased fructose 
intake for 2 weeks.5 It is interesting that 
a complex system such as the RAAS, 
which works on several levels, seems to 
be unable to equalize either the electro-
lyte imbalance or the slight increase in the 
blood pressure at an early stage (∆9 mm 
Hg in mice). Unfortunately, the authors do 
not state at what time point the decreased 
expression of renin was observed.
The metabolic experiments were very 
well conducted and provide sound verifi-
cation of the thesis that fructose reduced 
renal excretion of chloride and sodium. 
Rats were placed in metabolic cages, and 
24-hour urine chloride and sodium excre-
tion was determined before and after 
placement on a high-fructose diet. The 
resulting data demonstrate a significant 
decrease in chloride and sodium excre-
tion of the kidney after switching from the 
control diet to the high-fructose diet for 
4 days. The authors explain the complex-
ity of the pathogenesis of hypertension by 
referencing studies on a pathophysiologi-
cal interference of ouabain, an endogenous 
Na-K-ATPase inhibitor. Ouabain is dem-
onstrated to regulate excessive salt reten-
tion in various mouse models from day 5 
after the start of an increased-fructose diet 
by enhancing salt excretion in the kidney. 
The question arises of why the chloride and 
sodium excretion was determined with the 
metabolic cage for only 4 days instead of 
covering the expected increase in sodium 
excretion occurring after day 5.
The detection of a similar distribution 
pattern of PAT1 and Glut5 on the apical 
membrane in jejuna in mice as well as the 
demonstration of a similar distribution 
pattern and labeling intensity of Glut5 in 
jejuna of Slc26a6+/+ and Slc26a6–/– mice 
using western blot analysis and immuno-
fluorescence labeling is ambiguous. In our 
experience,8 these assays yield unclear 
results and therefore warrant the use of 
other techniques, such as mass spectrom-
etry. Mass spectrometry, in combination 
with fragment mass spectrometry, is a con-
dicio sine qua non for a valid and unam-
biguous identification. The use of other 
methods based on techniques such as anti-
body reaction are not reliable, even if the 
collected data may be valid (Figure 1).
Recent studies have provided a dra-
matic turn in the field of fructose trans-
port. Vitart et al. demonstrated that Glut9 
(SLC2A9), a well-known fructose trans-
porter, is also capable of transporting 
urate.7 This amazing finding raises many 
important questions, not least of which is 
how an anion could compete for binding 
and transport with a sugar. The competi-
tion between urate and fructose in heter-
ologously expressed systems may provide 
the link between the hyperuricemia seen 
in the present study of Singh et al.5 and 
fructose. Clearly, more work needs to be 
done on the distribution and function of 
SLC2A9 in the kidney and intestine to 
solidify this link.
Despite its flaws, the study presented 
by Singh et al.5 is full of exciting data that 
provide not only a basis for stimulating 
discussion and intriguing ideas for fur-
ther investigation, but a strong motiva-
tion to do so.
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figure 1 | Ambiguous quantification of synthetic angiotensin A and synthetic angiotensin II 
by enzyme immunoassay. Concentrations used in the assay are given in picomoles per liter under 
the corresponding bars; each n = 5. Ang, angiotensin; AU, arbitrary units. Error bars, mean ± SEM. 
(Adapted with permission from ref. 8.) 
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